(HLN) Haleon - Ratings and Ratios
OralHealth, Vitamins, PainRelief, ColdRelief, DigestiveHealth
HLN EPS (Earnings per Share)
HLN Revenue
Description: HLN Haleon
Haleon plc is a global consumer healthcare company that develops, manufactures, and markets a diverse portfolio of products, including oral health, vitamins, and over-the-counter (OTC) medications. The companys brand portfolio includes well-known names such as Sensodyne, Centrum, and Panadol, among others. With a presence in multiple regions, including North America, Europe, and Asia Pacific, Haleon plc has established itself as a significant player in the consumer healthcare industry.
From a financial perspective, Haleon plc has a market capitalization of approximately $45.5 billion USD, indicating a substantial market presence. The companys price-to-earnings (P/E) ratio is around 23.57, with a forward P/E of 19.80, suggesting a relatively stable earnings outlook. Additionally, the return on equity (RoE) stands at 8.71%, indicating a moderate level of profitability. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating cash flow margin can be examined. For instance, a high gross margin could indicate a strong pricing power and competitive advantage, while a growing revenue stream could suggest successful product launches or expanding market share.
Some potential KPIs to monitor Haleon plcs performance include: 1. Revenue growth rate: to assess the companys ability to expand its top line. 2. Gross margin percentage: to evaluate the companys pricing power and production efficiency. 3. Research and development (R&D) expenditure as a percentage of revenue: to gauge the companys commitment to innovation and new product development. 4. Operating cash flow margin: to assess the companys ability to generate cash from its operations. 5. Debt-to-equity ratio: to evaluate the companys capital structure and financial leverage.
By analyzing these KPIs, investors and analysts can gain a more comprehensive understanding of Haleon plcs financial health, competitive position, and growth prospects, ultimately informing more informed investment decisions.
HLN Stock Overview
| Market Cap in USD | 44,172m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-07-22 |
HLN Stock Ratings
| Growth Rating | 61.5% |
| Fundamental | 58.5% |
| Dividend Rating | 44.8% |
| Return 12m vs S&P 500 | -21.9% |
| Analyst Rating | 4.0 of 5 |
HLN Dividends
| Dividend Yield 12m | 1.88% |
| Yield on Cost 5y | 2.56% |
| Annual Growth 5y | 23.26% |
| Payout Consistency | 100.0% |
| Payout Ratio | 47.6% |
HLN Growth Ratios
| Growth Correlation 3m | -45.8% |
| Growth Correlation 12m | 20.1% |
| Growth Correlation 5y | 90% |
| CAGR 5y | 20.01% |
| CAGR/Max DD 3y | 1.06 |
| CAGR/Mean DD 3y | 3.62 |
| Sharpe Ratio 12m | 0.93 |
| Alpha | -16.28 |
| Beta | 0.400 |
| Volatility | 18.75% |
| Current Volume | 7189.5k |
| Average Volume 20d | 7825.9k |
| Stop Loss | 9.3 (-3.9%) |
| Signal | -0.14 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.44b TTM) > 0 and > 6% of Revenue (6% = 674.0m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 1.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.52% (prev -31.82%; Δ 26.30pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 4.17b > Net Income 1.44b (YES >=105%, WARN >=100%) |
| Net Debt (7.91b) to EBITDA (2.42b) ratio: 3.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (8.98b) change vs 12m ago 95.41% (target <= -2.0% for YES) |
| Gross Margin 62.62% (prev 59.70%; Δ 2.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 34.10% (prev 33.19%; Δ 0.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.84 (EBITDA TTM 2.42b / Interest Expense TTM 394.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.02
| (A) -0.02 = (Total Current Assets 4.14b - Total Current Liabilities 4.76b) / Total Assets 31.83b |
| (B) 0.50 = Retained Earnings (Balance) 15.85b / Total Assets 31.83b |
| (C) 0.07 = EBIT TTM 2.30b / Avg Total Assets 32.94b |
| (D) 1.00 = Book Value of Equity 15.94b / Total Liabilities 15.89b |
| Total Rating: 3.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.48
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 5.21% = 2.60 |
| 3. FCF Margin 18.26% = 4.56 |
| 4. Debt/Equity 0.48 = 2.39 |
| 5. Debt/Ebitda 3.14 = -1.95 |
| 6. ROIC - WACC 0.62% = 0.78 |
| 7. RoE 8.82% = 0.73 |
| 8. Rev. Trend -6.81% = -0.51 |
| 9. EPS Trend -2.59% = -0.13 |
What is the price of HLN shares?
Over the past week, the price has changed by -0.62%, over one month by +0.31%, over three months by -9.15% and over the past year by -7.18%.
Is Haleon a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HLN is around 9.28 USD . This means that HLN is currently overvalued and has a potential downside of -4.13%.
Is HLN a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.6 | 20.1% |
| Analysts Target Price | 11.6 | 20.1% |
| ValueRay Target Price | 10.1 | 4.8% |
Last update: 2025-09-13 04:36
HLN Fundamental Data Overview
CCE Cash And Equivalents = 676.0m GBP (last quarter)
P/E Trailing = 21.9333
P/E Forward = 18.1488
P/S = 4.0087
P/B = 2.0364
P/EG = 2.9248
Beta = 0.238
Revenue TTM = 11.23b GBP
EBIT TTM = 2.30b GBP
EBITDA TTM = 2.42b GBP
Long Term Debt = 7.58b GBP (from longTermDebt, last quarter)
Short Term Debt = unknown (0.0)
Debt = 7.58b GBP (Calculated: Short Term 0.0 + Long Term 7.58b)
Net Debt = 7.91b GBP (from netDebt column, last fiscal year)
Enterprise Value = 39.38b GBP (32.48b + Debt 7.58b - CCE 676.0m)
Interest Coverage Ratio = 5.84 (Ebit TTM 2.30b / Interest Expense TTM 394.0m)
FCF Yield = 5.21% (FCF TTM 2.05b / Enterprise Value 39.38b)
FCF Margin = 18.26% (FCF TTM 2.05b / Revenue TTM 11.23b)
Net Margin = 12.84% (Net Income TTM 1.44b / Revenue TTM 11.23b)
Gross Margin = 62.62% ((Revenue TTM 11.23b - Cost of Revenue TTM 4.20b) / Revenue TTM)
Tobins Q-Ratio = 2.47 (Enterprise Value 39.38b / Book Value Of Equity 15.94b)
Interest Expense / Debt = 1.46% (Interest Expense 111.0m / Debt 7.58b)
Taxrate = 22.77% (435.0m / 1.91b)
NOPAT = 1.78b (EBIT 2.30b * (1 - 22.77%))
Current Ratio = 0.87 (Total Current Assets 4.14b / Total Current Liabilities 4.76b)
Debt / Equity = 0.48 (Debt 7.58b / last Quarter total Stockholder Equity 15.94b)
Debt / EBITDA = 3.14 (Net Debt 7.91b / EBITDA 2.42b)
Debt / FCF = 3.70 (Debt 7.58b / FCF TTM 2.05b)
Total Stockholder Equity = 16.35b (last 4 quarters mean)
RoA = 4.53% (Net Income 1.44b, Total Assets 31.83b )
RoE = 8.82% (Net Income TTM 1.44b / Total Stockholder Equity 16.35b)
RoCE = 9.62% (Ebit 2.30b / (Equity 16.35b + L.T.Debt 7.58b))
RoIC = 6.91% (NOPAT 1.78b / Invested Capital 25.74b)
WACC = 6.29% (E(32.48b)/V(40.05b) * Re(7.49%)) + (D(7.58b)/V(40.05b) * Rd(1.46%) * (1-Tc(0.23)))
Shares Correlation 3-Years: -13.96 | Cagr: 6.24%
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.07% ; FCFE base≈1.94b ; Y1≈2.21b ; Y5≈3.04b
Fair Price DCF = 11.74 (DCF Value 52.56b / Shares Outstanding 4.48b; 5y FCF grow 16.27% → 3.0% )
EPS Correlation: -2.59 | EPS CAGR: 0.90% | SUE: -0.03 | # QB: False
Revenue Correlation: -6.81 | Revenue CAGR: 1.80%
Additional Sources for HLN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle